WatchExperimental Drug Nearly Doubles Survival in Advanced Pancreatic Cancer, Drawing a Standing Ovation at ASCO
Daraxonrasib, a new RAS-targeting pill, extended median survival to 13.2 months versus 6.7 for chemotherapy in a 500-patient trial — a 60% reduction in the risk of death from one of medicine's deadliest cancers.























